Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 6;46(1):3.
doi: 10.1186/s40463-016-0179-6.

HPV DNA in saliva from patients with SCC of the head and neck is specific for p16-positive oropharyngeal tumours

Jason K Wasserman  1 , Ryan Rourke  2 , Bibianna Purgina  1 , Lisa Caulley  2 , Jim Dimitroulakos  3 , Martin Corsten  4 , Stephanie Johnson-Obaseki  5
Affiliations

HPV DNA in saliva from patients with SCC of the head and neck is specific for p16-positive oropharyngeal tumours

Jason K Wasserman et al. J Otolaryngol Head Neck Surg. .

Erratum in

Abstract

Background: Human papillomavirus (HPV) is an important cause of head and neck squamous cell carcinoma (HNSCC), especially in young people. These tumours overexpress p16 and respond well to treatment. The rapid detection of HPV in patients with HNSCC may expedite treatment when p16 status is not immediately available.

Methods: Saliva-based DNA collection kits and nested polymerase chain reaction (PCR) were used to determine the HPV status of 62 individuals with biopsy-proven HNSCC. Immunohistochemistry was used to determine tumour p16 status.

Results: A total of 62 patients were included in the study. Twenty-nine samples (47%) were positive for HPV DNA, the majority of which were high risk (HR) subtypes (79%). Patients who tested positive for HR HPV were more likely to have a tumour arising in the oropharynx compared to a non-oropharyngeal site (74 vs 26%; p = 0.003). A positive HR HPV saliva assay was 100% specific (95% CI 59-100%) and had a 100% positive predictive value (95% CI 75-100%) for a p16 positive tumour arising in the oropharynx. In contrast, a negative HR HPV assay had a 96% negative predictive value (95% CI 80-100%) for tumours arising in a non-oropharyngeal site. Independent of site, the saliva assay had a sensitivity of 77% (95% CI 54-91%) and a specificity of 94% (95% CI 77-99%), respectively, for a p16 positive tumour.

Conclusion: We show that a saliva based assay is an effective method for detecting HPV in patients with HNSCC and that a positive HR HPV test is highly specific for p16 positive tumours arising in the oropharynx. This simple and rapid test could be used in cases where a biopsy of the primary tumour is not readily available.

Keywords: Head and neck cancer; Human papillomavirus; Oropharyngeal cancer; Screening.

PubMed Disclaimer

References

    1. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342–350. doi: 10.1038/nrc798. - DOI - PubMed
    1. Humans IWGotEoCRt Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100:1–441. - PMC - PubMed
    1. McKaig RG, Baric RS, Olshan AF. Human papillomavirus and head and neck cancer: epidemiology and molecular biology. Head Neck. 1998;20:250–265. doi: 10.1002/(SICI)1097-0347(199805)20:3<250::AID-HED11>3.0.CO;2-O. - DOI - PubMed
    1. Johnson-Obaseki S, McDonald JT, Corsten M, et al. Head and neck cancer in Canada: trends 1992 to 2007. Otolaryngol Head Neck Surg. 2012;147:74–78. doi: 10.1177/0194599812437332. - DOI - PubMed
    1. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:4294–4301. doi: 10.1200/JCO.2011.36.4596. - DOI - PMC - PubMed

MeSH terms

Substances